<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="2038">Azacitidine</z:chebi>'s efficacy in therapy-related myeloid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (t-MN) has not been well-studied </plain></SENT>
<SENT sid="1" pm="."><plain>In our retrospective review of 84 t-MN patients treated with <z:chebi fb="0" ids="2038">azacitidine</z:chebi>, median overall survival (OS) was 14.5 months and overall response rate was 43%, including 11% complete remission, 4% marrow complete remission, and 11% partial remission </plain></SENT>
<SENT sid="2" pm="."><plain>In patients who underwent allogeneic transplant (25%), median OS was 19.2 versus 12.8 months (P=0.023) for those who did not </plain></SENT>
<SENT sid="3" pm="."><plain>Response rates were comparable to those reported for de novo <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>When we analyzed outcomes according to five scoring systems, only the Global MD Anderson Risk Model predicted survival with statistical significance </plain></SENT>
</text></document>